Liposomal resiquimod for the treatment of Leishmania donovani infection.

Peine, Kevin J; Gupta, Gaurav; Brackman, Deanna J; Papenfuss, Tracey L; Ainslie, Kristy M; Satoskar, Abhay R; Bachelder, Eric M

Peine, Kevin J; Gupta, Gaurav; Brackman, Deanna J; Papenfuss, Tracey L; Ainslie, Kristy M; Satoskar, Abhay R; Bachelder, Eric M.

Affiliation

Peine KJ; Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH 43210, USA.

J Antimicrob Chemother ; 69(1): 168-75, 2014 Jan.

Article in En | MEDLINE | ID: mdl-23956375

Subject(s)

Antiprotozoal Agents/administration & dosage; Imidazoles/administration & dosage; Leishmania donovani/drug effects; Leishmaniasis, Visceral/drug therapy; Liposomes/administration & dosage; Administration, Intravenous; Animals; Bone Marrow/parasitology; Disease Models, Animal; Interferon-gamma/metabolism; Interleukin-10/metabolism; Leishmania donovani/isolation & purification; Leishmaniasis, Visceral/parasitology; Leukocytes, Mononuclear/immunology; Liver/parasitology; Mice; Mice, Inbred BALB C; Parasite Load; Spleen/parasitology; Treatment Outcome

Key words

drug delivery; imidazoquinoline; therapy; visceral

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leishmania donovani / Imidazoles / Leishmaniasis, Visceral / Liposomes / Antiprotozoal Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Antimicrob Chemother Year: 2014 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google